HC Wainwright Weighs in on Xeris Biopharma Q1 Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Xeris Biopharma in a report issued on Friday, March 7th. HC Wainwright analyst O. Livnat expects that the company will post earnings of ($0.08) per share for the quarter. HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Xeris Biopharma’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Xeris Biopharma’s Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at $0.01 EPS and FY2029 earnings at $0.78 EPS.

Other research analysts have also recently issued reports about the company. Piper Sandler reiterated a “neutral” rating and issued a $4.00 price objective (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Jefferies Financial Group reiterated a “buy” rating and issued a $6.00 price objective (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Craig Hallum upped their price objective on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a report on Friday, March 7th. Finally, Leerink Partners upped their price objective on Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.92.

Xeris Biopharma Price Performance

Shares of Xeris Biopharma stock opened at $4.39 on Monday. The stock has a market cap of $654.47 million, a P/E ratio of -9.76 and a beta of 2.32. The stock’s 50 day simple moving average is $3.61 and its 200-day simple moving average is $3.28. Xeris Biopharma has a 1-year low of $1.69 and a 1-year high of $4.68.

Institutional Trading of Xeris Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. NewEdge Advisors LLC purchased a new stake in Xeris Biopharma in the fourth quarter valued at approximately $34,000. Wealth Enhancement Advisory Services LLC purchased a new stake in Xeris Biopharma in the third quarter valued at approximately $35,000. R Squared Ltd purchased a new stake in Xeris Biopharma in the fourth quarter valued at approximately $42,000. Quantbot Technologies LP purchased a new stake in Xeris Biopharma in the third quarter valued at approximately $44,000. Finally, Cibc World Markets Corp purchased a new stake in Xeris Biopharma in the fourth quarter valued at approximately $44,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.